1,290$
1,57%
Echtzeit-Aktienkurs Telomir Pharmaceuticals Inc
Bid:
Ask:
Echtzeit-Chart der Telomir Pharmaceuticals Inc Aktie
Fundamentaldaten der Telomir Pharmaceuticals Inc Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [USD] | - | -16,53 Mio. | -16,53 Mio. | -0,56 | - | - | - |
| 2023 [USD] | - | -13,07 Mio. | -13,07 Mio. | -0,44 | - | - | - |
| 2022 [USD] | - | -0,85 Mio. | -0,85 Mio. | -0,03 | - | - | - |
| 2021 [USD] | - | -0,14 Mio. | -0,14 Mio. | -0,01 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Telomir Pharmaceuticals Inc Aktie
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.